Oral Antibiotic for Uncomplicated Skin and Soft Tissue Infections
For uncomplicated skin and soft tissue infections, cephalexin 500 mg orally every 6 hours (or 500 mg every 12 hours for mild cases) is the recommended first-line oral antibiotic, targeting the most common pathogens—streptococci and methicillin-susceptible Staphylococcus aureus. 1
Primary Recommendation: Beta-Lactam Antibiotics
For typical uncomplicated SSTIs without purulent drainage or systemic signs of infection, beta-lactam antibiotics remain the cornerstone of therapy because they provide excellent coverage against streptococci, which are the predominant pathogens in non-purulent cellulitis. 1
First-Line Options:
- Cephalexin 500 mg orally every 6 hours (or 500 mg every 12 hours for streptococcal pharyngitis and uncomplicated skin infections) 1, 2
- Dicloxacillin 500 mg orally four times daily 1
- Amoxicillin 500 mg three times daily 1
- Penicillin 500 mg orally four times daily 1
Duration: 5-7 days is as effective as 10 days if clinical improvement occurs by day 5. 1
When to Consider MRSA Coverage
MRSA is an uncommon cause of typical non-purulent cellulitis—studies show 96% success rates with beta-lactams alone even in high-MRSA prevalence areas. 1 However, add MRSA coverage when:
- Purulent drainage is present 1
- Penetrating trauma, especially injection drug use 1
- Evidence of MRSA infection elsewhere 1
- Systemic signs of infection (SIRS criteria) 1
- Treatment failure with beta-lactam therapy 1
MRSA-Active Oral Options:
- Clindamycin 300-450 mg orally four times daily (covers both streptococci and MRSA) 1, 3
- Trimethoprim-sulfamethoxazole (TMP-SMX) 160-800 mg twice daily PLUS a beta-lactam (cephalexin or amoxicillin) for dual streptococcal/MRSA coverage 1
- Doxycycline 100 mg twice daily PLUS a beta-lactam for dual coverage 1
Critical caveat: TMP-SMX and doxycycline have unreliable activity against beta-hemolytic streptococci when used alone, so never use them as monotherapy for non-purulent cellulitis. 1 A recent double-blind trial confirmed that TMP-SMX plus cephalexin was no more effective than cephalexin alone for pure cellulitis without abscess. 1
Special Circumstances
Animal Bites:
Amoxicillin-clavulanate 500/875 mg twice daily is the preferred oral agent, providing coverage for Pasteurella multocida, streptococci, staphylococci, and anaerobes. 1
Human Bites:
Amoxicillin-clavulanate 500 mg every 8 hours covers Eikenella corrodens, streptococci, staphylococci, and anaerobes. 1
Penicillin Allergy:
- Clindamycin 300 mg three times daily (good for staphylococci, streptococci, and anaerobes) 1
- Fluoroquinolones (ciprofloxacin 500-750 mg twice daily, levofloxacin 750 mg daily, or moxifloxacin 400 mg daily) 1
Evidence Regarding Antibiotics vs. Drainage Alone
For simple abscesses, incision and drainage alone may be sufficient without antibiotics. A randomized placebo-controlled trial showed 90.5% cure rates with drainage alone versus 84.1% with drainage plus cephalexin in MRSA-predominant abscesses. 4 However, add antibiotics when:
- Erythema extending >5 cm from wound edge 1
- Systemic signs (temperature >38.5°C, heart rate >110 bpm) 1
- Multiple lesions 1
- Immunocompromised state 1
Pediatric Considerations
For children with uncomplicated SSTIs, cephalexin 25-50 mg/kg/day in divided doses is appropriate, with the option to divide doses every 12 hours for streptococcal pharyngitis and skin infections. 2 A pediatric randomized trial found no significant difference between cephalexin and clindamycin for CA-MRSA infections when appropriate drainage was performed, emphasizing that fastidious wound care and close follow-up are more important than initial antibiotic choice. 5
Common Pitfalls to Avoid
- Do not routinely cover for MRSA in non-purulent cellulitis—this leads to unnecessary broad-spectrum antibiotic use. 1
- Do not use TMP-SMX or doxycycline as monotherapy for cellulitis without purulent drainage due to poor streptococcal coverage. 1
- Do not prescribe antibiotics for simple abscesses if adequate drainage is achieved and no systemic signs are present. 4
- Avoid fluoroquinolones in children <18 years and tetracyclines in children <8 years. 1